Search Results 151-160 of 13122 for Tyrosine

  1. Publications - Yul W. Yang, M.D., Ph.D. - Mayo Clinic

    ... tyrosine kinase inhibitor acneiform eruptions. J Am Acad Dermatol 2021 Mar; 84 (3):840-841 Epub 2020 Oct 08. View PubMed; Yang YW, Lehrer MD, Mangold AR ...

  2. Clinical trials - Oncology (Medical)

    Patients with ALK aberrant tumors (ALK tyrosine kinase mutation or ALK amplification) will be non-randomly assigned to receive crizotinib added to current COG ...

  3. Clinical trials - Oncology (Medical)

    Patients with ALK aberrant tumors (ALK tyrosine kinase mutation or ALK amplification) will be non-randomly assigned to receive crizotinib added to current COG ...

  4. Mayo Clinic Proceedings: In the Limelight, December 2021

    Several clinical observations indicate that improved glycemic control may attend the use of tyrosine kinase inhibitors (TKIs), agents introduced some 20 years ...

  5. Clinical trials - Oncology (Medical)

    Patients with ALK aberrant tumors (ALK tyrosine kinase mutation or ALK amplification) will be non-randomly assigned to receive crizotinib added to current COG ...

  6. Clinical trials - Oncology (Medical)

    Patients with ALK aberrant tumors (ALK tyrosine kinase mutation or ALK amplification) will be non-randomly assigned to receive crizotinib added to current COG ...

  7. Clinical trials - Oncology (Medical)

    This study will also allow participants who are currently progressing on a Bruton tyrosine kinase inhibitor (BTKi) and requiring salvage therapy as assessed ...

  8. Clinical trials - Oncology (Medical)

    This study will also allow participants who are currently progressing on a Bruton tyrosine kinase inhibitor (BTKi) and requiring salvage therapy as assessed ...

  9. Study of Two Doses of MK-3475 (Pembrolizumab) Versus Docetaxel in Previously-Treated Participants With Non-Small Cell Lung Cancer (MK-3475-010/KEYNOTE-010) - Mayo Clinic

    ... tyrosine kinase inhibitor therapy or completed palliative radiotherapy within 7 days of the first dose of study drug; Prior therapy with an anti-programmed ...

  10. Hematology - Clinical trials

    This study will also allow participants who are currently progressing on a Bruton tyrosine kinase inhibitor (BTKi) and requiring salvage therapy as assessed ...